InduPro’s Post

Big thanks to all who joined our Lunch and Learn event with MassBio! Your engagement and insights made it a success. Special shoutout to our speakers Dr. Lei Shi and Dr. Victor Goldmacher for their brilliant presentations on accelerating antibody development and ADCs. We hope to see you in our next events! 🙌 If you missed it, don’t worry – read our recap here 👇 https://lnkd.in/estmvdXa Topics included: • Maytansinoids and auristatins as payloads, e.g. Kadcyla • Challenges in ADC development, including bystander cytotoxicity of linkers • ADCs effective in eradication of tumors with heterogeneous expression of target antigen, e.g. Elahere • Solutions for the next generations of ADCs or other Ab-based cytotoxic agents, such as superior payload transport to lysosomes, bypassing internalization, and ADC-mimetics #Biointron #Antibodies #LunchAndLearn #MassBio #Event #Biotech #ADC #Boston

iPSCs offer insights into disease mechanisms and promise for cell therapies, but face challenges like safety, understanding reprogramming, and directing cell differentiation. Watch our latest video to learn more about the history, applications, and essential steps in iPSC research and development. Learn more: https://ow.ly/2pO250QyAHr #iPSCs #StemCellResearch #RegenerativeMedicine #PersonalizedMedicine #CellTherapy #Biotech #ScienceInnovation #ResearchAndDevelopment

Our latest In Focus with Sino Biological, Inc. discusses the use of cytokines in immunotherapy, the challenges they present and the techniques that can be used to overcome those challenges and engineer more effective cytokines. >>> https://hubs.ly/Q02HcrRS0

📰 Always nice to see tenant updates in Endpoints News! Granza Bio (YC W24)'s Felicis and Refactor led $7m seed round, aided by Y Combinator, has caught its eye this time. 👨🏾🔬 👨🏾🔬 Ashwin Menon Nandakumar and Ashwin Jainarayanan, alongside academic Michael Dustin, founded the University of Oxford spin-out to develop attack particles, using the immune system to treat cancer and autoimmune diseases. ➡ Here's the article https://lnkd.in/eFMEnUwj #oxfordinnovation

Introducing a faster, automation friendly workflow, with unparalleled sensitivity; Parse Biosciences' Evercode Mega enables 1M cells & 96 samples, at a fraction of the cost of competing technologies, in a couple of days. It's time to leave droplet-based single cell behind-so you can see more for less. #drugdiscovery #singlecellanalysis #singlecell #oncologyresearch #ngs #rnaseq

Available for #License: Researchers at Emory University have developed a fluorescently labeled approach based on the magnitude of molecular forces transmitted through cell adhesion receptors for evaluating mechanical forces in cells. This technology has potential to improve the understanding of various diseases in basic research while promoting the development of new diagnostics and therapeutics. Developed by Rong Ma and Khalid Salaita. Learn more about this exciting technology here: https://lnkd.in/gEKsAHKS

Need differentiated cells on your iPSC patient specific lines? Or do you have a unique line that poorly differentiates with your own protocol and you need help? If you face such challenges let Trailhead assist - this is one way where the power of HD-DoE can help. #ipsc #pluripotent #stemcell #drugdiscovery #trailbio #hddoe #cellmanufacturing #biomanufacturing #qbd #designofexperiments

If you are attending the ASGCT Annual Meeting in Baltimore: Visit my colleague Anna Camus and me at our poster #1778. For the first time we will present our preclinical data on editing and shielding T cells from Alemtuzumab, while preserving CD52‘s expression and anti-phagocytic function. This will protect engineered T cells from Alemtuzumab-mediated lymphodepletion and at the same time prevent increased phagocytosis, which is observed with CD52 knock-out.

How does one take the first step into the antibody industry? In this episode of The Chain, Tariq Ghayur talks with Janine Schuurman, the new president of The Antibody Society, about her inspiration to get into antibody engineering, her impressive career at Genmab, her advice for achieving a productive work environment, and her current work. Dr. Schuurman also shares insights on staying innovative, how to deal with the challenges of the industry, and why young scientists in the industry should not be afraid to fail. Listen now https://lnkd.in/eWy2wYB3 #antibodydiscovery #antibodytherapeutics #antibody

Axol Bioscience is the first choice for functional microglia cells, derived from iPSCs to support drug screening. We are excited to see our clients bringing microglia to larger and larger screening platforms, utilizing manual and automated platforms and increasingly high density plates. Why leading labs are using axoCells™ microglia : • High-quality, relevant microglia that express the three key markers (IBA–1, TMEM119 and P2RY12) and demonstrate robust functional activity measured by cytokine release, phagocytosis and chemotaxis • Save time with functionally mature cells available in just 7 days • Ensure confidence with high-quality cells manufactured in our ISO:9001-accredited production facility under rigorous quality control procedures • Designed for use in mono-, co- and tri-culture models Learn more and ask for a quote: https://hubs.la/Q02KydXz0 #iPSCs #StemCells #Microglia #DrugScreening